Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 13 of the 30 sources its claims cite were checked for support.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
CoChat Summary
TL;DR
In a single-arm trial, fecal microbiota transplantation (FMT) from anti–PD-1 responders plus pembrolizumab was well tolerated and produced clinical benefit in 6 of 15 evaluable patients with PD-1–refractory melanoma. Responders showed donor microbiome implantation, increased CD8+ T cell activation, and reduced IL-8–expressing myeloid cells.
Key findings
- Among 15 evaluable patients, objective responses occurred in 3 (20%: one complete response, two partial responses), and durable stable disease lasting >12 months occurred in another 3 (20%), for clinical benefit in 6 of 15. Median progression-free survival and overall survival were 3.0 and 7.0 months overall, and 14.0 and 14.0 months in the six patients with disease control.
- FMT caused durable gut microbiota perturbation; responders’ microbiota shifted toward donor composition, whereas nonresponders were heterogeneous. Responders also had greater donor bacteria–specific IgG responses and enrichment of taxa previously linked to anti–PD-1 response, including Firmicutes and Actinobacteria, with decreases in Bacteroidetes.
- Responders showed higher post-treatment CD56+CD8+ T cells, increased CD8+ T cell activation/differentiation markers, and more granzyme B–expressing MAIT cells. Tumor single-cell RNA sequencing showed fewer myeloid cells and regulatory T cells in responders, with lower myeloid CXCL8/IL-8 and SPP1 expression.
- Serum profiling showed responders had decreased circulating CCL2, CXCL8/IL-8, IL-18, IL-12p70, and IFN-γ, and increased IL-21, CXCL13, type II cytokines, and TNF-family cytokines. Metabolomic/lipidomic changes included more efficient primary-to-secondary bile acid conversion and altered triacylglycerol/monoacylglycerol/diacylglycerol levels. A transkingdom network of 371 nodes and 819 edges linked microbial taxa to host metabolomic and proteomic features.
Methods
- Single-arm clinical trial (NCT03341143) in patients with metastatic melanoma primary refractory to anti–PD-1. Sixteen patients were enrolled; 15 received colonoscopic FMT from seven anti–PD-1 responder donors plus pembrolizumab and were evaluable for response.
- Serial blood and stool sampling was performed, with infectious screening for 32 agents before FMT. Response was assessed by RECIST v1.1 every 12 weeks.
- Analyses included shotgun metagenomic sequencing of 223 fecal samples from recipients and donors, multiparameter flow cytometry of PBMCs, single-cell RNA sequencing of 64,340 CD45+ cells from 17 tumor samples, serum cytokine/chemokine profiling, metabolomics/lipidomics, and transkingdom network analysis.
Limitations
- The paper states that findings are preliminary and warrant evaluation in a larger randomized clinical trial; it also notes that insufficient tumor tissue was available to assess tumor mutation burden, PD-L1 expression, or IFN-γ gene expression signature as predictors of outcome.
- The text makes evident that the study is small and single-arm, limiting causal inference and comparison with standard-of-care outcomes; some analyses, such as the speed of microbiome change, did not reach statistical significance, which the authors attribute to limited sample size.
- The text also makes evident heterogeneity in nonresponders’ donor microbiota implantation and notes that nonresponse may reflect patient immunodeficiency, lack of tumor immunogenicity, absence of necessary taxa in the FMT, or failure of FMT implantation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the gut microbiome is a major tumor-extrinsic regulator of responses to anti–PD-1 (6–9).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [6] Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G, Eur. J. Immunol 45, 17– 31 (2015). 25328099 sourceExperimental — accuracy not yet measured
In 'The commensal microbiota controls the response to cancer therapy' our copy confirms that the gut microbiota modulates responses to cancer immunotherapy, chemotherapy, TBI and adoptive T-cell transfer (via myeloid-cell conditioning; see also Fig. 2 legend in Concluding remarks). But for checkpoint blockade the paper states only a hypothesis: after noting progress with anti-CTLA-4/anti-PD-1 antibodies [107], it says the data 'suggest the possibility that the microbiota may also modulate the clinical effectiveness of this new class of anticancer drugs.' The citing sentence therefore presents as an established, major regulator of anti-PD-1 responses what this source explicitly hedges as a suggested possibility, and no anti-PD-1 microbiome experiment is reported in our copy. (LLM, conf=0.78)
- Not checked yetcites [7] Finlay BB, Nat. Rev. Immunol 20, 522– 528 (2020). 32661409 source
- Partly supportedcites [8] Goldszmid RS, Cancer Immunol. Res 3, 103– 109 (2015). 25660553 PMC4324508 sourceExperimental — accuracy not yet measured
In 'Impact of commensal microbiota on cancer therapy' our copy states that 'The gut microbiota influences the response to cancer immunotherapy and chemotherapy by affecting the differentiation and functions of myeloid cells in the tumor microenvironment', and documents microbiota/antibiotic effects on CpG-ODN plus anti-IL10R, cyclophosphamide, oxaliplatin, TBI and adoptive CD8+ T-cell transfer — so the tumor-extrinsic, myeloid-priming part of the claim is supported. However, PD-1 appears only in 'Clinical perspectives' as one of the successful checkpoint approaches ('inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1/2'), with no linkage to microbiota; the paper instead only speculates that 'the variable response to cancer therapy observed in patients may be in part due to different microbiota composition'. Searches for 'anti-PD-1', checkpoint-blockade response and microbiota-control-of-checkpoint-efficacy returned no passage tying the microbiome to anti–PD-1 outcomes, so the specific anti–PD-1 qualifier of the claim is not supported by this source (it likely rests on the other references in the cluster 6–9). (LLM, conf=0.72)
- Could not verifycites [9] Zarour HM, Clin. Cancer Res 22, 1856– 1864 (2016). 27084739 PMC4872712 sourceExperimental — accuracy not yet measured
Our copy of Zarour (2016) is complete and discusses tumor-extrinsic drivers of anti-PD-1 response only in terms of the tumor microenvironment: soluble mediators (IL-10, IDO, VEGF-A, adenosine/A2aR, CSF-1R), suppressive cells (Tregs, TAM/MDSC), metabolic checkpoints (hypoxia/HIF-1α) and mutational/neoepitope burden correlating with clinical response (Therapeutic Strategies section). No passage mentions the gut microbiome, microbiota, or antibiotics; searches for 'gut microbiome/microbiota regulates response to anti-PD-1', 'microbiota composition antibiotic impact immunotherapy efficacy tumor-extrinsic', and 'bacterial composition fecal transplant' returned only TME-related and reference-list passages. The paper therefore neither supports nor contradicts the attributed claim. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that successful implantation and mucosal trans-location of the transplanted bacteria, known to induce an IgG response against commensal bacteria, may preferentially occur in Rs (18).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant induces persistent perturbation of recipients’ gut microbiome
What the sources say
- Supportedcites [18] Zeng MY, Immunity 44, 647– 658 (2016). 26944199 PMC4794373 source
The clause the citation is offered for is the background fact that mucosal translocation of gut bacteria is what induces an IgG response against commensal bacteria; the 'preferentially occur in Rs' inference is the citing authors' own conclusion from their FMT data and is not attributed content. Our copy states exactly that mechanism: the Results section 'Homeostatic Induction of Systemic IgG to Gram-Negative Symbiotic Bacteria' concludes that a selective group of gram-negative symbiotic bacteria breach the intestinal epithelial barrier and disseminate systemically to induce IgG, backed by detection of bacterial 16S rRNA in spleens/MLNs and Enterobacteriaceae being the predominant translocated families, and the Introduction/Discussion describe translocation-driven systemic IgG to symbiotic (commensal) bacteria. The only slippage is contextual — Zeng et al. studied resident murine symbionts under homeostatic conditions, not donor/transplanted bacteria or FMT responders — but the mechanism attributed to this source is stated there. (LLM, conf=0.82)
hedgedstates a possible causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“administration of certain gut commensals or fecal microbiota transplantation (FMT) promotes anti–PD-1 efficacy in melanoma-bearing mice (10–12).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s FMT experiments (Fig. 4G–I; page unavailable) report reduced tumor growth and improved response to anti-PD-L1 therapy in mice receiving stool from patients who responded to anti-PD-1, compared with stool from nonresponders. Our copy does not report administering individual gut commensals to mice or testing anti-PD-1 efficacy in those mice. (LLM, conf=0.90)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the indexed copy (section labeled Abstract; no page given), fecal transfer from responding patients improved tumor control in melanoma-bearing mice, and anti–PD-L1 treatment was effective in mice colonized with responder microbiota. The mouse experiment tested anti–PD-L1, not anti–PD-1; the copy also does not show that administering individual commensal species improved checkpoint-treatment efficacy in those mice. (LLM, conf=0.88)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, composition of the gut microbiome modulates therapeutic activity of anti–PD-1 and anti–programmed death-ligand 1 (PD-L1)”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 source
The mouse FMT experiments (Results, Fig. 4G–I passage) state that germ-free mice transplanted with stool from anti–PD-1 responders had significantly reduced tumor growth (p=0.04) versus NR-FMT recipients, and that 'mice transplanted with R-FMT also exhibited improved responses to anti-PD-L1 therapy (Fig. 4I) in contrast to mice that were transplanted with stool from NR (NR-FMT)' — i.e. microbiome composition modulated therapeutic activity of both agents in mice. The abstract likewise reports enhanced anti-tumor immunity 'in germ-free mice receiving fecal transplants from responding patients,' and the closing discussion generalizes to modulation of anti–PD-1 response. The claim's mouse-only scope matches what the paper demonstrates causally in mice. (LLM, conf=0.87)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
Our copy supports the anti–PD-L1 half of the claim with the paper's own in vivo data: in germ-free mice reconstituted with fecal material from responder versus nonresponder patients, 'Anti–PD-L1 was markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice (Fig. 3F)' (Results, Abstract section), and the Abstract states reconstitution with responder feces gave 'greater efficacy of anti-PD-L1 therapy'. However, this study did not administer anti–PD-1 to mice — its patient-level anti–PD-1 association is clinical (42 metastatic melanoma patients), and the mouse evidence for microbiome modulation of anti–PD-1 is explicitly credited to other work: 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)... fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (Discussion). The intro likewise frames the mouse microbiome/anti–PD-L1 precedent as preclinical studies of reference (4). The attribution of the anti–PD-1-in-mice component to this source is therefore not supported by it. (LLM, conf=0.80)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple circulating cytokines and chemokines decreased after FMT in Rs, including CCL2 (MCP1), CXCL8 (IL-8), and IL-18 that have been associated with negative outcomes to anti–PD-1 (32, 33), and IL-12p70 and IFN-γ (Fig. 4A, heatmap).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant alters serum metabolome and cytokines in responders
What the sources say
- Could not verifycites [32] Gok Yavuz B, Sci. Rep 9, 3172 (2019). 30816272 PMC6395633 sourceExperimental — accuracy not yet measured
Our copy of Yavuz et al. (2019) is an in vitro study of cancer-associated fibroblasts educating CD14+ monocytes/macrophages from healthy donors; it contains no FMT cohort, no patient serum cytokine measurements, and no statement about CCL2/MCP-1, CXCL8/IL-8 or IL-18 levels changing after treatment or being associated with anti-PD-1 outcomes. The closest passages are the Results section 'Recruitment of monocytes by CAFs might be mediated by MCP-1 as well as SDF-1 cytokines' (blocking MCP-1 reduced monocyte migration in vitro) and the Discussion on PD-1+ TAMs citing Gordon et al. and Topalian et al., neither of which addresses circulating cytokine change or immunotherapy outcome association. Searched: 'CCL2 MCP-1 CXCL8 IL-18 negative outcomes anti-PD-1' and 'fecal microbiota transplantation responders serum cytokines' — no supporting passage. (LLM, conf=0.75)
- Not checked yetcites [33] Terme M, Cancer Res. 71, 5393– 5399 (2011). 21724589 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
28 more claims
Create a free account to see all 56 claims and to verify the 17 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In two proof-of-concept trials with a total of 26 patients, responder-derived fecal microbiota transplantation (FMT) overcame PD-1 resistance in a third of patients with melanoma, suggesting that microbiome modulation could improve responsiveness to anti-PD-1 ICB10,11.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concurs with another clinical trial with a similar FMT-ICB design in which Akk was also associated with response to ICB post-FMT (Davar et al., 2021).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Davar et al. (2021) found that combining FMT with anti-PD-1 therapy in refractory melanoma patients led to meaningful changes in gut microbial composition, increased activation of CD8+ natural killer-like T cells, recirculation of mucosa-associated invariant T cells, and distinct metabolic shifts associated with enhanced antitumor responses.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of two phase 1 clinical studies NCT03341143 and NCT03353402 showed responder-derived FMT effectively relieved the resistance to α-PD-1/PD-L1 in some melanoma patients, having implications for modulating gut microbiota in cancer immunotherapy [26, 317].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
33 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Cited by
Items 201–300 of 1,002
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
Wu, J., Wang, S., Zheng, B. J., Qiu, X., Wang, H., & Chen, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669150 · Cited by 83
“Another research also focused on anti-PD-1 therapy in advanced melanoma, and they found that FMT and anti-PD-1 changed tumor microenvironment and gut microbiome which led to overcoming resistance of anti-PD-1 immunotherapy (87).”
BackgroundSelf-citationYang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 83
“In addition, a fecal microbiota transplant has been proven to promote the response to anti–PD-1 therapy by reprogramming the tumor microenvironment in immunotherapy-refractory melanoma patients [187,188].”
BackgroundThe potential role of the microbiota in prostate cancer pathogenesis and treatment
Pernigoni, N., Guo, C. W., Gallagher, L., Yuan, W., Colucci, M., Troiani, M., Liu, L., Maraccani, L., Guccini, I., Migliorini, D., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00795-2 · Cited by 77
“…by clinical evidence from a phase I trial, which showed a 20% (3/15) response rate in patients with melanoma with primary resistance to anti-PD1 therapy after receiving an anti-PD1 antibody in combination with single-donor-derived FMT from a durable responder to anti-PD1 antibody treatment 168 .”
BackgroundGang, X., Yan, J., Li, X., Shi, S., Xu, L., Liu, R. M., Cai, L., Li, H., & Zhao, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217241 · Cited by 80
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
Chen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67
Uribe‐Herranz, M., Beghi, S., Ruella, M., Parvathaneni, K., Salaris, S., Κωστόπουλος, Ν., George, S. S., Pierini, S., Krimitza, E., Costabile, F., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.012 · Cited by 71
The role of the gut microbiota in tumor, immunity, and immunotherapy
Xie, Y., & Liu, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410928 · Cited by 77
The Microbiome and Cancer: A Translational Science Review
Fernandez, E., Wargo, J. A., & Helmink, B. A. (2025) · JAMA · doi:10.1001/jama.2025.2191 · Cited by 95
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar, D., Morrison, R. M., Dzutsev, A., Karunamurthy, A. D., Chauvin, J.-M., Amatore, F., Deutsch, J. S., das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.007 · Cited by 80
Self-citationRandrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 73
“Very recently, two publications have reported approximately 30% responses when FMT from responders to immunotherapy was combined with reinductionwith checkpoint blockade for patientswithmelanomawho were considered refractory to immunotherapy (93, 94).”
BackgroundČierniková, S., Ševčíková, A., Drgoňa, Ľ., & Mego, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188990 · Cited by 75
Microbiota and body weight control: Weight watchers within?
Boscaini, S., Leigh, S., Lavelle, A., García‐Cabrerizo, R., Lipuma, T., Clarke, G. A., Schellekens, H., & Cryan, J. F. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101427 · Cited by 74
Song, M., Liang, J., Wang, L., Li, W., Jiang, S., Xu, S., Tang, L., Du, Q., Liu, G., Meng, H., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110757 · Cited by 74
Lin, Y., Xie, M., Lau, H. C.-H., Zeng, R., Zhang, R., Wang, L., Li, Q., Wang, Y., Chen, D., Jiang, L., et al. (2024) · Med · doi:10.1016/j.medj.2024.10.007 · Cited by 82
Oh, B., Boyle, F. M., Pavlakis, N., Clarke, S. J., Eade, T., Hruby, G., Lamoury, G., Carroll, S. L., Morgia, M., Kneebone, A. B., et al. (2021) · Cancers · doi:10.3390/cancers13194824 · Cited by 78
“Recently two breakthrough clinical studies reported that FMT to non-responders, from donors who had a complete response to anti-PD-1 refractory metastatic melanoma, showed a clinical response to ICIs in a subset group of anti-PD-1 refractory metastatic melanoma patients when they received a combination of FMT and anti…”
BackgroundResultInfluentialWang, N., Wu, S., Huang, L., Hu, Y., He, X., He, J., Hu, B., Xu, Y., Rong, Y., Yuan, C., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01117-x · Cited by 62
“The alteration of the microbiome profile in FMT recipients may enhance the therapeutic activity of FMT through competitive growth [159, 160].”
Ferrari, V., Lo Cascio, A., Melacarne, A., Tanasković, N., Mozzarelli, A. M., Tiraboschi, L., Lizier, M., Salvi, M., Braga, D., Algieri, F., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.014 · Cited by 60
Glioma and the gut–brain axis: opportunities and future perspectives
Dono, A., Nickles, J., Rodriguez-Armendariz, A. G., McFarland, B. C., Ajami, N. J., Ballester, L. Y., Wargo, J. A., & Esquenazi, Y. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac054 · Cited by 68
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 60
“Among these gut microorganisms, Akkermansia muciniphila (Akk), has emerged as a potential hallmark of clinical benefit to ICI [104], and FMT combined with ICIs changes intestinal flora and improves tumor microenvironment to overcome ICIs resistance [105].”
BackgroundMicrobiome as a biomarker and therapeutic target in pancreatic cancer
Pourali, G., Kazemi, D., Chadeganipour, A. S., Arastonejad, M., Kashani, S. N., Pourali, R., Maftooh, M., Akbarzade, H., Fiuji, H., Hassanian, S. M., et al. (2024) · BMC Microbiology · doi:10.1186/s12866-023-03166-4 · Cited by 78
“Better outcomes have been recorded in the treatment of a variety of malignancies using immunotherapy [114, 115], fecal microbial transplantation [116], prebiotics and probiotics [117, 118], and antibiotics [119, 120] that lead to changes in microbial diversity, thus affecting treatment or…”
BackgroundDeLeon, O., Mocanu, M., Tan, A., Sidebottom, A. M., Koval, J., Ceccato, H. D., Kralicek, S. E., Colgan, J. J., George, M. M. S., Lake, J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.05.014 · Cited by 72
Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 77
Bautista, J., Maceiras, M. L., Hidalgo‐Tinoco, C., Guerra-Guerrero, A., Betancourt-Velarde, A., & López‐Cortés, A. (2026) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00883-8 · Cited by 77
The role of microbiome in pancreatic cancer
Li, J., Zhu, M., Kashyap, P., Chia, N., Tran, N. H., McWilliams, R. R., Bekaii‐Saab, T., & Ma, W. W. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09982-2 · Cited by 66
Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy
Singh, A., Alexander, S., & Martin, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1114499 · Cited by 73
“observed in a clinical study that FMT can help to overcome resistance to anti-PD-1 therapy (pembrolizumab), resulting in clinical benefits in 6 out of 15 patients (23, 24).”
BackgroundKamath, S., Stringer, A. M., Prestidge, C. A., & Joyce, P. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2233900 · Cited by 60
“Pembrolizumab is a selective IgG4-κ humanized monoclonal antibiotic targeting programmed cell death receptors-1 (PD-1) in melanoma [90].”
BackgroundMethodInfluentialRoles of microbiota in pancreatic cancer development and treatment
Cruz, M. S., Tintelnot, J., & Gagliani, N. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320280 · Cited by 68
“103,104 Here, transplantation of gut microbiota isolated from responder patients combined with anti-PD-1 treatment induced responses in patients that were previously anti-PD-1--refractory.”
BackgroundUsing mathematical modelling and AI to improve delivery and efficacy of therapies in cancer
Harkos, C., Hadjigeorgiou, A. G., Voutouri, C., Kumar, A. S., Stylianopoulos, T., & Jain, R. K. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00796-w · Cited by 79
“Both preclinical and clinical studies have demonstrated that dietary interventions and faecal microbiota transplantation from patients who respond to therapy to patients who do not respond to therapy can improve the patient response to immune checkpoint inhibitors 165,166 .”
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Kiousi, D. E., Kouroutzidou, A. Z., Neanidis, K., Karavanis, E., Matthaios, D., Pappa, A., & Galanis, Α. (2023) · Cancers · doi:10.3390/cancers15072101 · Cited by 76
“Indeed, recent clinical studies show that FMT from donors showing complete response to treatments augmented the effects of ICI in a subset of melanoma patients, showing promise for further investigation [93,94].”
BackgroundEmerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets
Dai, J.-H., Tan, X.-R., Qiao, H., & Liu, N. (2023) · Protein & Cell · doi:10.1093/procel/pwad052 · Cited by 59
“…clinical trials have assessed the safety and feasibility of ICI responder-derived FMT and confirmed that FMT can beneficially modulate the composition of the gut microbiota and increase the clinical efficacy of immunotherapy in melanoma patients (Baruch et al., 2021; Davar et al., 2021).”
BackgroundGut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products
Kim, D.-Y., Lee, S.-Y., Lee, J., Whon, T. W., Lee, J., Jeon, C. O., & Bae, J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2412376 · Cited by 67
Saadh, M. J., Allela, O. Q. B., Ballal, S., Mahdi, M. S., Chahar, M., Verma, R., Al-Hussein, R. K. A., Adil, M., Jawad, M. J., & Al-Nuaimi, A. M. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152398 · Cited by 74
Dai, S., Chen, Y., Cai, W., Dong, S., Zhao, J., Chen, L., & Cheng, C. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01739-6 · Cited by 73
“Among these, fecal microbiota transplantation (FMT), which transfers stool from ICI responders to non-responders, has demonstrated the capacity to enhance immunotherapy response in both preclinical models and early-phase clinical studies [155, 156].”
Porcari, S., CICCARESE, C., Heidrich, V., Rondinella, D., Quaranta, G., Severino, A., Arduini, D., Buti, S., Fornarini, G., Primi, F., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04189-2 · Cited by 67
“Notably, we did not use antibiotic preconditioning, as this trial was started before our discovery of its association with microbiome engraftment 31 and the publication of relevant studies 7,8 .”
Microbiota and Colorectal Cancer: From Gut to Bedside
Silva, M. G., Brunner, V., & Tschurtschenthaler, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760280 · Cited by 66
The human microbiome in clinical translation: from bench to bedside
Bautista, J., Echeverría, C. E., Maldonado-Noboa, I., Ojeda-Mosquera, S., Hidalgo-Tinoco, C., & López-Cortés, A. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1632435 · Cited by 55
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
Valdivielso, J. M., Balafa, O. C., Ekart, R., Ferro, C. J., Mallamaci, F., Mark, P. B., Rossignol, P., Sarafidis, P. A., Vecchio, L. D., & Ortíz, A. (2021) · Drugs · doi:10.1007/s40265-021-01555-5 · Cited by 62
Dey, P., Chaudhuri, S. R., Efferth, T., & Pal, S. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.09.026 · Cited by 59
The critical role of tumor microbiome in cancer immunotherapy
Yang, L., Wang, Q., He, L., & Sun, X. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2301801 · Cited by 55
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 71
“50,52 Melanoma patients with baseline Bacillota -dominant microbiota (including Ru-minococcus and Lachnospiraceae) experienced an improved clinical response to ipilimumab and longer OS (Table 1).”
BackgroundInfluentialCurrent Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 80
Di Luccia, B., Molgora, M., Khantakova, D., Jaeger, N., Chang, H.-W., Czepielewski, R. S., Helmink, B. A., Onufer, E. J., Fachi, J. L., Bhattarai, B., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi5374 · Cited by 59
How microbiota improve immunotherapy
Ansaldo, E., & Belkaid, Y. (2021) · Science · doi:10.1126/science.abl3656 · Cited by 54
Self-citationHong, Y., Li, H., Chen, L., Su, H., Zhang, B., Luo, Y. H., Li, C., Zhao, Z., Shao, Y., & Guo, L. (2024) · Microbiome · doi:10.1186/s40168-024-01795-z · Cited by 65
“It had been recently demonstrated that some gut microorganisms could overcome resistance to antitumor drugs [61].”
BackgroundTong, Y., & Lou, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638352 · Cited by 68
“In oncology, FMT has shown promise in improving ICI ef fi cacy, with studies in melanoma (137, 138) and other cancers (14) linking positive responses to favorable microbiota shifts and potentially altered BA metabolism.”
Kong, F., Fang, C., Zhang, Y., Duan, L., Du, D., Xu, G., Li, X., Li, H., Yin, Y., Xu, H., et al. (2022) · Advanced Science · doi:10.1002/advs.202105523 · Cited by 60
The Food Recognition Benchmark: Using Deep Learning to Recognize Food in Images
Mohanty, S. P., Singhal, G., Scuccimarra, E. A., Kebaili, D., Héritier, H., Boulanger, V., & Salathé, M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.875143 · Cited by 72
“For example, it has been shown that the gut microbiota affects the immune system, drug metabolism, and the effect of immune therapies against cancer (4–6).”
BackgroundRecent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
Ohtani, N., Kamiya, T., & Kawada, N. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000241 · Cited by 63
“In one trial, 3 of 10 patients,[100] and in another, 6 of 15 patients showed increased ICI efficacy.[101] Specifically, treatment with FMT resulted in antitumor changes, including increased CD8+ T cell activation.”
BackgroundCao, F., Jin, L., Zhang, C., Gao, Y., Qian, Z., Wen, H., Yang, S., Ye, Z., Hong, L., Huang, Y., et al. (2023) · Advanced Materials · doi:10.1002/adma.202304257 · Cited by 66
Zhang, Y., Liu, X., Wei, Z., Zhang, J., Aiting, W., Wang, J., Lin, Y., Bangwei, C., & Yan, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107033 · Cited by 62
Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota
Li, H., Dong, T., Tao, M., Zhao, H., Lan, T., Yan, S., Gong, X., Hou, Q., Ma, X., & Song, Y. (2024) · Food & Function · doi:10.1039/d3fo04807a · Cited by 55
Turjeman, S., Rozera, T., Elinav, E., Ianiro, G., & Koren, O. (2025) · Cell · doi:10.1016/j.cell.2025.01.038 · Cited by 58
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
Current Trends and Challenges of Fecal Microbiota Transplantation—An Easy Method That Works for All?
Almeida, C., Oliveira, R., Baylina, P., Fernandes, R., Teixeira, F. G., & Barata, P. (2022) · Biomedicines · doi:10.3390/biomedicines10112742 · Cited by 56
Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols
Hamamah, S., Gheorghita, R. E., Lobiuc, A., Sîrbu, I. O., & Covașă, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1060581 · Cited by 60
“Interestingly, two recent studies have found that FMT may improve the response to monoclonal antibody therapy in patients with advanced melanoma (23, 119).”
BackgroundInfluentialPotential links between the microbiota and T cell immunity determine the tumor cell fate
Mohseni, A. H., Taghinezhad‐S, S., Casolaro, V., Lv, Z., & Li, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05560-2 · Cited by 55
“The findings of two newly published clinical trials indicated that SCFAproducing bacteria such as Lachnospiraceae-enriched FMT enhanced anti-PD-1 immunotherapy and augmented CD8 T cell infiltration in melanoma patients [35, 36].”
ResultUnraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, R., Huemer, F., Steiner, M., Gonzalez-Martinez, A., Greil, R., & Weiss, L. (2023) · Cancers · doi:10.3390/cancers15205090 · Cited by 52
“Fecal microbiota transplantation from melanoma patients responding to ICIs to patients with primary resistance to ICIs is able to induce responses and/or long-lasting disease stabilization upon ICI rechallenge [95,96].”
BackgroundLiposomes-enabled cancer chemoimmunotherapy
Zhang, L., Shi, J., Zhu, M., Huang, Y., Lu, Q., Sun, P., Chen, H., Lai, X. P., & Fang, C. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122801 · Cited by 60
The tumor microbiome in cancer progression: mechanisms and therapeutic potential
Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 64
“A phase II clinical trial showed that the combination of FMT and the anti-PD-1 pembrolizumab achieved a disease control rate of 40% in the treatment of patients with PD-1-resistant advanced melanoma [290].”
Butyrate, a new microbiota-dependent player in CD8+ T cells immunity and cancer therapy?
Danne, C., & Sokol, H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100328 · Cited by 51
“This is an open access ar of treated patients, associated with increased CD8 T cell activation and infiltration in both the gut lamina propria and the tumor microenvironment.(8,9) CD8 T cells are considered the most important actors of anticancer immunity.”
BackgroundRadiation injury and gut microbiota-based treatment
Wang, W., Cui, B., Nie, Y., Sun, L., & Zhang, F. (2023) · Protein & Cell · doi:10.1093/procel/pwad044 · Cited by 58
“2021, Davar et al .”
Jiang, S., Ma, W., Ma, C., Zhang, Z., Zhang, W., & Zhang, J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2341717 · Cited by 57
“244,245 Distinct features were observed in the responsive and nonresponsive melanoma patients’ gut microbes.”
BackgroundLong-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 58
Mariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 78
“A study with 16 patients with melanoma went a step further and described a sensitization of tumor cells to PD-L1 therapy after fecal transplant (from responders to non-responders) in six patients [121].”
The interactions between oral-gut axis microbiota and Helicobacter pylori
Chen, X., Wang, N., Wang, J., Liao, B., Cheng, L., & Ren, B. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.914418 · Cited by 61
Liu, X., Lu, B., Tang, H. T., Jia, X., Zhou, Q., Zeng, Y., Gao, X., Chen, M., Xu, Y., Wang, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105427 · Cited by 58
Tumor microbiome: roles in tumor initiation, progression, and therapy
Zhang, S., Huang, J., Jiang, Z., Tong, H., Ma, X., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00248-9 · Cited by 63
Self-citationHuang, M., Ji, Q., Huang, H., Wang, X., & Wang, L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2486519 · Cited by 57
Microbiota-derived metabolites: Key modulators of cancer immunotherapies
Perl, M., Fante, M. A., Herfeld, K., Scherer, J. N., Poeck, H., & Orberg, E. T. (2025) · Med · doi:10.1016/j.medj.2025.100773 · Cited by 66
“153,154 Exploring metabolite combinations offers a promising strategy for fine-tuning anti-tumor immunity, given their distinct mechanisms of action.”
Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light
Zhang, J., Wu, K.-H., Shi, C., & Li, G. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01027-2 · Cited by 56
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 56
“Increased CD8 T cell activation and reduced myeloid cell were identified (185).”
BackgroundDysbiotic Gut Microbiota-Derived Metabolites and Their Role in Non-Communicable Diseases
Tan, J., Taitz, J., Nanan, R. K. H., Grau, G. E., & Macia, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015256 · Cited by 63
“This effect is reversible, as faecal transplantation from melanoma patients that responded to anti-PD1 immunotherapy to non-responder patients increased their response to anti-PD1, as well as their CD8 + T cell activation [110].”
BackgroundLiao, Q., Zhou, X., Wu, L., Yang, Y., Zhu, X., Liao, H., Zhang, Y., Lian, W., Zhang, F., Wang, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181243 · Cited by 58
Self-citationAn update on fecal microbiota transplantation for the treatment of gastrointestinal diseases
Waller, K. M. J., Leong, R. W. L., & Paramsothy, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15731 · Cited by 55
Harness the functions of gut microbiome in tumorigenesis for cancer treatment
Lee, M. (2021) · Cancer Communications · doi:10.1002/cac2.12200 · Cited by 50
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 51
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
“Another study demonstrated that fecal microbiota transplant could overcome resistance to anti-PD-1 therapy in melanoma patients 114 .”
BackgroundD’Alise, A. M., Leoni, G., Cotugno, G., Siani, L., Vitale, R. L., Ruzza, V., Garzia, I., Antonucci, L., Micarelli, E., Venafra, V., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3940 · Cited by 55
“Moreover, Lachnospir-aceaebelongstothegroupofBacteroidespreviouslyshowntocorrelate positively with the rescue of clinical response to anti-PD-1 by fecal transplant (25).”
Li, Y., Ye, Z., Zhu, J., Fang, S., Meng, L., & Zhou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844335 · Cited by 45
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy
Qin, Y., Huo, M., Liu, X., & Li, S. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368749 · Cited by 62
Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 53
“The use of extracted microbiota from the feces of cancer patients who responded well to PD-1 for FMT in cancer patients who did not respond to PD-1 surprisingly found that these patients achieved long-term survival after receiving PD-1 treatment (pembrolizumab) again (Davar et al. 2021).”
BackgroundThe impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
“[171] verified the efficacy of FMT in anti-PD-1 immunotherapy in patients with metastatic melanoma for the first time in a clinical trial.”
MethodMicrobiota in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Guan, D., Wang, Z., Li, X., Dong, S., Huang, J., & Zhou, W. (2023) · MedComm · doi:10.1002/mco2.417 · Cited by 50
Xia, L., Zhu, X., Wang, Y., & Lü, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217123 · Cited by 56
Tseng, C., Wong, S. H., Yu, J. Q., Lee, Y. Y., Terauchi, J., Lai, H., Luo, J., Kao, C., Yu, S., Liou, J., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334501 · Cited by 54
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 54
“FMT has also been reported to overcome resistance to ICIs in patients with cancer, with good tolerability and no severe irAEs 170,171 .”
Lin, A., Huang, L., Jiang, A., Zhu, L., Mou, W., Li, Y., Zhang, C., Liu, Z., Zhang, J., Cheng, Q., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04183-y · Cited by 46
“In the realm of immunotherapy, FMT is considered a highly promising adjunct strategy to enhance ICI efficacy by modulating the gut microbiome in some large-scale clinical trials, thereby improving clinical outcomes (34,35).”
Microbiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 61
Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
Pirš, B., Škof, E., Smrkolj, V., & Smrkolj, Š. (2022) · Cancers · doi:10.3390/cancers14030631 · Cited by 52
Hakozaki, T., Nolin-Lapalme, A., Kogawa, M., Okuma, Y., Nakamura, S., Moreau-Amaru, D., Tamura, T., Hosomi, Y., Takeyama, H., Richard, C., et al. (2022) · Cancers · doi:10.3390/cancers14215405 · Cited by 52
“Moreover, several strategies to shift the GM composition to increase the response to ICIs are currently being evaluated in the clinical setting [10,11], and fecal microbiota transplantation has been shown to overcome secondary resistance to ICIs.”
BackgroundKim, C. G., Koh, J.-Y., Shin, S.-J., Shin, J.-H., Hong, M., Chung, H. C., Rha, S. Y., Kim, H. S., Lee, C.-K., Lee, J. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101251 · Cited by 45
“35,36 In these two first-in-human studies, 35,36 patients who were previously refractory to ICIs underwent fecal microbiota transplantation using stool collected from patients with complete or partial response to immune checkpoint blockade, following which they were treated with PD-1 blockade.”
BackgroundThe conundrum of breast cancer and microbiome - A comprehensive review of the current evidence
Papakonstantinou, A., Nuciforo, P. G., Borrell, M., Zamora, E., Pimentel, I., Saura, C., & Oliveira, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102470 · Cited by 51
Gut microbial structural variation associates with immune checkpoint inhibitor response
Liu, R., Zou, Y., Wang, W.-Q., Chen, J.-H., Zhang, L., Feng, J., Yin, J.-Y., Mao, X.-Y., Li, Q., Luo, Z.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42997-7 · Cited by 45
Exploring the role of gut microbiota in advancing personalized medicine
Huang, G., Khan, R., Zheng, Y., Lee, P.-C., Li, Q., & Khan, I. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1274925 · Cited by 50
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 55
Pan-cancer atlas of tumor-resident microbiome, immunity and prognosis
Sheng, D., Jin, C., Yue, K., Yue, M., Liang, Y., Xue, X., Li, P., Zhao, G., & Zhang, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217077 · Cited by 48
Rebeck, O. N., Wallace, M. J., Prusa, J., Ning, J., Evbuomwan, E. M., Rengarajan, S., Habimana-Griffin, L., Kwak, S., Zahrah, D., Tung, J., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.10.013 · Cited by 49
Metadata
- Authors
- Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A. A., Schwartz, M. B., Dubner, H. M., Ernst, S. J., Rose, A., Najjar, Y. G., Belkaid, Y., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M.
- Affiliations
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
- Oregon State University (US)
- National Institutes of Health (US)
- Corresponding author
- Davar, Diwakar
- Dzutsev, Amiran K.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- ORCID
- Davar, Diwakar
- Dzutsev, Amiran K.
- McCulloch, John A.
- Rodrigues, Richard R.
- Chauvin, Joe-Marc
- Morrison, Robert M.
- Pagliano, Ornella
- Zidi, Bochra
- Zhang, Shuowen
- Badger, Jonathan H.
- Vetizou, Marie
- Cole, Alicia M.
- Fernandes, Miriam R.
- Prescott, Stephanie
- Costa, Raquel G. F.
- Balaji, Ascharya K.
- Morgun, Andrey
- Vujkovic-Cvijin, Ivan
- Wang, Hong
- Borhani, Amir A.
- Schwartz, Marc B.
- Dubner, Howard M.
- Najjar, Yana G.
- Belkaid, Yasmine
- Kirkwood, John M.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 595-602
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8097968
- OpenAlex
- W3126208996
- Cited by
- 1,781
- References
- 54
- Citations by year
- 2026: 396 · 2025: 328 · 2024: 315 · 2023: 316 · 2022: 282 · 2021: 141
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA228181, CA222203)
- Melanoma Research Foundation (MRFBC 2020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, melanoma, immunotherapy resistance, gut microbiota, CD8+ T cell activation, interleukin-8, myeloid cells, immunosuppression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Humans, Lymphocyte Activation, Melanoma, Skin Neoplasms, Interleukin-8, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Myeloid Cells, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.